What is Verve Therapeutics Earnings Power Value (EPV)?
As of Mar24, Verve Therapeutics's earnings power value is $6.41. *
* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.
Margin of Safety is
N/A.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.
Verve Therapeutics Earnings Power Value (EPV) Historical Data
The historical data trend for Verve Therapeutics's Earnings Power Value (EPV) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Verve Therapeutics Earnings Power Value (EPV) Chart
|
Verve Therapeutics Annual Data
|
|
Trend |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Earnings Power Value (EPV) |
|
- |
- |
- |
- |
- |
|
Verve Therapeutics Quarterly Data
|
|
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Earnings Power Value (EPV) |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of Verve Therapeutics's Earnings Power Value (EPV)
For the Biotechnology subindustry, Verve Therapeutics's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Verve Therapeutics's Earnings Power Value (EPV) Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Verve Therapeutics's Earnings Power Value (EPV) distribution charts can be found below:
* The bar in red indicates where Verve Therapeutics's Earnings Power Value (EPV) falls into.
Verve Therapeutics Earnings Power Value (EPV) Calculation
Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.
Verve Therapeutics (Verve Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
201 Brookline Avenue, Suite 601, Boston, MA, USA, 02215
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.
Executives
| Krishna Yeshwant |
director, 10 percent owner |
C/O GOOGLE VENTURES 2011, L.P., 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043 |
| Allison Dorval |
officer: Chief Financial Officer |
C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821 |
| Fred T. Fiedorek |
officer: Chief Medical Officer |
55 BALDWIN LANE, PRINCETON NJ 08540 |
| Joan Nickerson |
officer: Chief Administrative Officer |
C/O VERVE THERAPEUTICS, INC., 201 BROOKLINE AVENUE, SUITE 601, BOSTON MA 02215 |
| Andrew Bellinger |
officer: Chief Scientific Officer |
500 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
| Gv 2017 Gp, L.l.c. |
10 percent owner |
1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043 |
| Alphabet Inc. |
other: Member of 10% Group |
1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043 |
| Sekar Kathiresan |
director, 10 percent owner, officer: Chief Executive Officer |
500 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
| Lonnel Coats |
director |
8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381 |
| Fmr Llc |
10 percent owner, other: See Remark 1 |
245 SUMMER STREET, BOSTON MA 02210 |
| Alexander Cumbo |
director |
215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142 |
| Burt A Adelman |
director, 10 percent owner |
DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803 |
| Andrew D. Ashe |
officer: See Remarks |
C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803 |
| Logos Global Management Lp |
10 percent owner |
1 LETTERMAN DRIVE, BLDG C, SUITE C3-350, SAN FRANCISCO CA 94129 |
| Cormorant Asset Management, Lp |
10 percent owner |
200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Verve Therapeutics (Verve Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VERV has been successfully added to your